<DOC>
	<DOCNO>NCT02267460</DOCNO>
	<brief_summary>Enrollment include approximately 30 AA4500 naïve subject . Subjects divide degree penile curvature randomize 1:1 ratio one follow treatment group : - AA4500 investigator model - AA4500 without investigator model Each subject receive 2 injection AA4500 , separate approximately 24 hour 72 hour , repeat 42 day ( ± 5 day ) 4 treatment cycle . Approximately 14 day second injection AA4500 , subject visit study site investigator ass subject instruct subject appropriate use ErecAid® Esteem® Manual Vacuum Therapy System .</brief_summary>
	<brief_title>An Open-label Study Assess Safety Effectiveness AA4500 Combination With ErecAid® Esteem® Manual Vacuum Therapy System Treating Men With Peyronie 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Penile Induration</mesh_term>
	<criteria>Be male ≥ 18 year age Have symptom ( ) Peyronie 's disease evidence stable disease determine investigator Have penile curvature least 30° dorsal , lateral , dorsal/lateral plane screening . It must possible delineate single plane maximal curvature evaluation study Be judge good health , base upon result medical history , physical examination , laboratory profile Voluntarily sign date inform consent agreement approve Independent Ethics Committee ( IEC ) . Be able read , complete understand various rating instrument English . Has penile curvature le 30° great 90° screen visit Has follow condition : Chordee presence absence hypospadias Thrombosis dorsal penile artery and/or vein Infiltration benign malignant mass result penile curvature Infiltration infectious agent , lymphogranuloma venereum Ventral curvature cause Presence active sexually transmitted disease Known active hepatitis B C Known immune deficiency disease positive human immunodeficiency virus ( HIV ) Has history spontaneous priapism ( ie , erection last four hour ) Has previously undergo surgery Peyronie 's disease Fails erection , opinion investigator , sufficient accurately measure subject 's penile deformity administration prostaglandin E1 Has calcify plaque evident appropriate radiographic evaluation , penile ultrasound would prevent proper injection study medication . Noncontiguous stipple calcium acceptable inclusion provide calcium deposit interfere injection AA4500 plaque Has isolate hourglass deformity penis Has plaque cause curvature penis locate proximal base penis , injection local anesthetic would interfere injection AA4500 plaque Has previously receive alternative medical therapy Peyronie 's disease administer intralesional route ( include , limited , steroid , verapamil , naturally occur low molecular weight protein , interferonα2b ) within 3 month first dose study drug plan use medical therapy time study Has receive alternative medical therapy Peyronie 's disease administer oral ( include , limited , vitamin E [ &gt; 500 U ] , potassium aminobenzoate [ Potaba ] , tamoxifen , colchicine , pentoxifylline , overthecounter erectile dysfunction medication , steroidal antiinflammatory drug ) topical route ( include , limited , verapamil apply cream ) within 3 month first dose study drug plan use medical therapy time study Has extracorporeal shock wave therapy ( ESWT ) correction Peyronie 's disease within 6month period screen plan ESWT time study Has use mechanical type device correction Peyronie 's disease within 2week period screen plan use device ( except prescribe protocol ) time study Has use mechanical device induce passive erection within 2week period screen plan use device ( except prescribe protocol ) time study Has significant erectile dysfunction fail respond oral treatment phosphodiesterase type 5 ( PDE5 ) inhibitor Has penile Duplex Doppler ultrasound evaluation screening show compromise penile hemodynamics opinion investigator clinically significant Has uncontrolled hypertension , determine investigator Has know recent history stroke , bleeding , significant medical condition , investigator 's opinion would make subject unsuitable enrollment study Has sickle cell trait disease , multiple myeloma , Hodgkin 's lymphoma , and/or blood dyscrasia carry risk clot priapism Has impairment hand ( ) would prevent safe use vacuum pump , determine investigator Is unwilling unable cooperate requirement study include completion schedule study visit Has receive investigational drug treatment within 30 day first dose study drug Has know allergy collagenase excipient AA4500 Has know allergy concomitant medication require per protocol Has coagulation disorder Is take medication chronic anticoagulation ( except ≤ 150 mg aspirin daily ) Has receive collagenase treatment within 30 day first dose study drug Has , time , receive AA4500 treatment Peyronie 's disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Peyronie 's disease</keyword>
	<keyword>penile plaque</keyword>
	<keyword>penile curvature</keyword>
</DOC>